When discussing autism spectrum disorder (autism), a common question arises in the office: Is there a medication for autism? The answer is yes and no. Psychotherapy is first line for the core symptoms like deficits in communication and restrictive and repetitive behaviors. No medications are approved by the FDA to target core symptoms directly. However, there are medications and supplements that can help manage common co-occurring symptoms.

Atypical antipsychotics
The FDA has approved risperidone and aripiprazole for irritability associated with autistic disorder in pediatric patients (ages 6–17). In a recent head-to-head trial, both medications had similar efficacy and tolerability, though risperidone was less likely to raise prolactin (Panda PK et al, Brain Dev 2025;47(5):104454). Trials have tested other antipsychotics for this use, but with inconsistent results (Fallah MS et al, J Child Adolesc Psychopharmacol 2019;29(3):168–180). However, antipsychotics have significant risks, and children and adolescents are more vulnerable to their sedative and metabolic effects. They are best reserved for significant aggression and the shortest duration necessary (Scahill L et al, J Am Acad Child Adolesc Psychiatry 2016;55(5):415–423).

ADHD medications
Patients with autism may have ADHD symptoms or meet full criteria for comorbid ADHD. Methylphenidate and atomoxetine are effective for hyperactivity and inattention in autism, but their efficacy and tolerability are more favorable in pure ADHD. Guanfacine and clonidine improve both ADHD symptoms and repetitive behaviors in autism (Joshi G et al, J Psychopharmacol 2021;35(3):203–210; Martins PLB et al, Prog Neuropsychopharmacol Biol Psychiatry 2024;134:111089).

Antidepressants
Antidepressants have been studied for stereotyped and repetitive behaviors, particularly SSRIs and SNRIs. However, the results vary. A 2022 meta-analysis found benefits for irritability, repetitive behaviors, and global symptoms (Liang SC et al, J Psychiatry Neurosci 2022;47(4):E299–E310). Older patients respond better than younger patients, a trend consistent with studies of antidepressants in depression. Overall, antidepressants have small and inconsistent benefits in autism. They are more reliable when used on label for comorbid depression and anxiety.

Melatonin
Melatonin may help sleep-related disorders in children and adolescents with autism. The American Academy of Neurology guidelines recommend melatonin when behavioral strategies are ineffective, emphasizing the need for high-purity products (Williams Buckley A et al, Neurology 2020;94(9):392–404). Lab-tested brands include Dr. Wurtman’s, Swanson, Trader Joe’s Chewable, Natrol, and Pure Encapsulations SR. Melatonin is dosed 1–3 hours before bed, starting at 1–3 mg and titrated as needed to a maximum of 10 mg nightly. Evidence for other hypnotics in autism is limited, but clonidine, ramelteon, gabapentin, and the orexin antagonists are often used in practice (Mammarella V et al, Expert Rev Neurother 2023;23(12):1261–1276).

Memantine
Memantine is hypothesized to target glutamate dysregulation, which plays a role in social communication and interaction. Results of randomized trials are mixed, but suggest a benefit for social impairments in patients without intellectual disability (Aboul-Fotouh S et al, Neurosci Biobehav Rev 2025;169:106019). True to its mechanism, the benefits are more pronounced in patients with glutamate dysregulation. However, memantine can cause impulsivity and agitation in autism (Elnaiem W et al, Hum Psychopharmacol 2022;37(5):e2841).

Leucovorin (folinic acid)
Leucovorin is a prescription form of folate that has recently found itself at the center of a regulatory whirlwind. In an unusual move, the FDA announced plans to approve leucovorin for autism at the urging of the White House in September 2025. Medical journals denounced the approval, which was only supported by three small placebo-controlled trials, all of which had flaws and one of which was retracted for statistical problems. In March 2026, the agency walked back the decision, approving leucovorin instead for central folate deficiency (CFD) with a positive CFD-FOLR1 gene, a rare genetic cause of autistic symptoms that affects several dozen people worldwide.

CFD may play a broader role in autism, where approximately 75% of patients have folate receptor alpha autoantibodies that impede folate’s transport across the blood-brain barrier (Ramaekers VT et al, Mol Psychiatry 2013;18(3):270–271). Leucovorin bypasses these receptors and allows folate to enter the central nervous system, where it is essential for neurotransmitter synthesis and brain health. Though the trials of leucovorin in autism are preliminary, they do suggest improvements in social communication and interaction, particularly in children with elevated folate receptor alpha autoantibodies (Renard E et al, Biochimie 2020;173:57–61; Frye RE et al, Mol Psychiatry 2018;23(2):247–256; Zhang C et al, Nutrients 2025;17(9):1602).

Leucovorin is safe and well tolerated, but it lacks large-scale trials, and there are no trials in adults. If you start it, stick with the prescription form, as over-the-counter folinic acid is not available in therapeutic doses.

Other supplements
Supplements are well tolerated, but the evidence in autism is inconsistent and based on small trials. Omega-3 fatty acids address inflammatory pathways implicated in autism. They may improve language and reduce irritability and hyperactivity, especially when started before age 8 and used for longer than 3 months, but the results are not consistent (Abbasi H et al, Nutr Res Rev 2025;38(2):546–557).

N-acetylcysteine is hypothesized to play a role in autism pathophysiology through its anti-glutamatergic and antioxidant properties. It has preliminary, positive results for irritability and hyperactivity when used adjunctively with risperidone (Nikoo M et al, Clin Neuropharmacol 2015;38(1):11–17). Other supplements, including L-carnosine, L-serine, and sulforaphane, have been evaluated in fewer, smaller studies with inconsistent results.

Treatment Options: Dosing and Significant Risks

Treatment	Dose	Significant Risks
Risperidone	0.5–3 mg/day	Metabolic changes, EPS, TD, NMS, QT prolongation
Aripiprazole	5–15 mg/day
Methylphenidate	0.125–1.5 mg/kg/day	Cardiac risks
Atomoxetine	0.5–1.4 mg/kg/day, max 100 mg/day	Cardiac risks, suicidal ideation
Antidepressants	SSRIs and SNRIs, dosed in ranges used for depression	Suicidal ideation, serotonin syndrome
Melatonin	Start 1–3 mg nightly, max 10 mg nightly	Well tolerated
Memantine	Daily dose of 3 mg (< 20 kg), 6 mg (20–39 kg), 9 mg (40–59 kg), 15–20 mg (≥ 60 kg)	Impulsivity and agitation
Leucovorin (folinic acid)	2 mg/kg/day, max 50 mg/day	Masks B12 deficiency
Omega-3 fatty acids	700–1500 mg/day (EPA + DHA)	Well tolerated
N-acetylcysteine (NAC)	600–900 mg/day
Sulforaphane	50–150 μmol/day
L-carnosine	10–15 mg/kg/day

CARLAT VERDICT
Psychotherapy is first line for autism, but medications and supplements also have a role. The FDA-approved risperidone and aripiprazole are best reserved for physical aggression, while methylphenidate, atomoxetine, antidepressants, melatonin, memantine, and leucovorin may target specific symptoms.